Read here for an analysis of LifeVantage's (LFVN) stock surge post GLP-1 trial, cautioning on pricing, retention, and ...

People with type 2 diabetes and obesity who develop kidney disease may benefit more from bariatric surgery than from GLP-1 ...

Viking Therapeutics, Inc.'s stock surged 1,500% on the promising obesity drug VK-2735, with Phase 3 trials and potential for ...

几十年来，医疗界一直在寻找治疗肥胖症的有效药物，直到GLP-1的出现。它还有个拗口的名字：胰高血糖素样肽-1。这是一种存在于肠道中的多肽，能够通过增强胰岛素分泌的方式抑制高血糖素分泌，从而降低血糖。

E arlier this month, Kourtney Kardashian’s supplement brand, Lemme, joined the growing market for Ozempic dupes with the ...

Employers that cover GLP-1s are partnering with vendors to design benefits and manage lifestyle programs, but the "jury is ...

导读在医疗领域，GLP-1（胰高血糖素样肽-1）药物正逐步超出传统减肥药物的范畴。          事实上，科学家发现，这类药物不仅在帮助人们减轻体重方面效果显著，更在酒精成瘾、帕金森病等多种疾病的治疗中展现出广泛的临床价值。

In an interview with Peers & Perspectives in Oncology, Sherry Shen, MD, discusses the GLP-1 agonists analyzed for weight ...

Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body ...

The companies will deliver products for diabetes and weight control in specific nations across the Middle East.

Discover an untold biotech story and find out how Pfizer missed an opportunity in the GLP-1 market because of an exit in the ...

A study highlights that GLP-1 RAs are linked to a reduced risk of cirrhosis in patients with MASLD and diabetes. Learn more ...